ERC-SG-LS4
ERC-SG-LS4
Programme: H2020
95 projects · €139,333,593 total EU contribution (project-level) · 72 participating organizations · 17 countries with participants
Total EU funding
Sum of EC max contribution fields for distinct projects in this topic.
€139,333,593
Countries active
Participant organizations by country (headquarters in CORDIS).
- Germany (16)
- UK (11)
- CH (6)
- Spain (6)
- France (5)
- IL (5)
- Netherlands (5)
- BE (4)
- Italy (3)
- FI (2)
- SE (2)
- AT (1)
- DK (1)
- EL (1)
- NO (1)
- SG (1)
- TR (1)
Open calls
From the EU Funding & Tenders Portal, linked to this topic code when it matches the call identifier. Sync via yarn etl:funding.
No open or forthcoming calls linked to this topic in the database yet.
Top organizations
By number of distinct projects in this topic.
- INSERM7 projects · FR
- KI4 projects · SE
- MPG4 projects · DE
- THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE4 projects · UK
- VLAAMS INSTITUUT BIOTECHNOLOGIE FLANDERS INSTITUTE FOR BIOTECHNOLOGY4 projects · BE
- WEIZMANN4 projects · IL
- THE HEBREW UNIVERSITY OF JERUSALEM3 projects · IL
- UNIVERSITY COLLEGE LONDON3 projects · —
- AMC2 projects · NL
- CERBM-GIE2 projects · FR
- CNIC2 projects · ES
- INSTITUT CURIE FONDATION2 projects · FR
Projects
Page 1 of 10
| Project | Programme | EU contribution | Total cost | |
|---|---|---|---|---|
Metastability of proteins during tumor metastasis METAMETA · 311522 | FP7 | €1,366,800 | €1,366,800 | Details |
The Role of Elimination of Senescent Cells in Cancer Development ELIMINATESENESCENT · 309688 | FP7 | €1,500,000 | €1,500,000 | Details |
Understanding computational roles of new neurons generated in the adult hippocampus AN07AT · 208132 | FP7 | €1,991,743 | €1,991,743 | Details |
Reversibility and tissue specificity of mitochondrial translation defects in early childhood REVERSIBLECOX · 309548 | FP7 | €1,432,075 | €1,432,075 | Details |
The Synapse Nanomap NANOMAP · 201936 | FP7 | €1,670,000 | €1,670,000 | Details |
Investigating the therapeutic potential of manipulating the IGF-IGFBP1 axis in the prevention and treatment of cardiovascular disease, diabetes and obesity BP-CarDiO · 310747 | FP7 | €1,493,543 | €1,493,543 | Details |
ALK as a common target for the pathogenesis and therapy in lymphoma, lung carcinoma and neuroblastoma LUNELY · 242965 | FP7 | €1,010,000 | €1,010,000 | Details |
Adipose tissue mass regulation in lean and obese individuals HUFATREG · 261258 | FP7 | €1,500,000 | €1,500,000 | Details |
RNA-based regulation of signal transduction – Regulation of calcineurin/NFAT signaling by microRNA-based mechanisms CALMIRS · 311549 | FP7 | €1,499,528 | €1,499,528 | Details |
Uncovering the mechanisms of inflammation induced liver tissue destruction and carcinogenesis LIVERCANCERMECHANISM · 261317 | FP7 | €1,212,190 | €1,212,190 | Details |